These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37875785)

  • 1. Modern diagnostics and treatment of Merkel cell carcinoma.
    Weilandt J; Peitsch WK
    J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
    Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
    Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease.
    Siqueira SOM; Campos-do-Carmo G; Dos Santos ALS; Martins C; de Melo AC
    An Bras Dermatol; 2023; 98(3):277-286. PubMed ID: 36870886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Merkel Cell Carcinoma Therapeutic Update.
    Cassler NM; Merrill D; Bichakjian CK; Brownell I
    Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
    Gehrcken L; Sauerer T; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune checkpoint inhibition in Merkel cell carcinoma].
    Terheyden P; Mohr A; Langan EA
    Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Periocular Merkel Cell Carcinoma - an overview of clinical aspects and current therapeutic options].
    Esser E; Grünewald I; Mihailovic N
    Laryngorhinootologie; 2024 Jun; 103(6):404-412. PubMed ID: 38128577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
    Gaiser MR; Bongiorno M; Brownell I
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.
    Becker JC; Stang A; Schrama D; Ugurel S
    Am J Clin Dermatol; 2024 Jul; 25(4):541-557. PubMed ID: 38649621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts and approaches to merkel cell carcinoma.
    Babadzhanov M; Doudican N; Wilken R; Stevenson M; Pavlick A; Carucci J
    Arch Dermatol Res; 2021 Apr; 313(3):129-138. PubMed ID: 32666149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and preclinical treatment options for Merkel cell carcinoma.
    Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
    Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Merkel cell carcinoma].
    Drusio C; Becker JC; Schadendorf D; Ugurel S
    Hautarzt; 2019 Mar; 70(3):215-227. PubMed ID: 30701288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer.
    Akaike T; Nghiem P
    J Dermatol Sci; 2022 Jan; 105(1):2-10. PubMed ID: 34836718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma.
    Shalhout SZ; Emerick KS; Kaufman HL; Silk AW; Thakuria M; Miller DM
    J Immunother; 2022 Sep; 45(7):299-302. PubMed ID: 35877101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
    Ricco G; Andrini E; Siepe G; Mosconi C; Ambrosini V; Ricci C; Casadei R; Campana D; Lamberti G
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merkel cell carcinoma.
    Patel P; Hussain K
    Clin Exp Dermatol; 2021 Jul; 46(5):814-819. PubMed ID: 33252781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
    Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.